DEF: Elevance Health Reports Strong 2025, Focuses on Whole Health

Elevance Health reported 13% operating revenue growth to $197.6 billion in 2025, alongside strategic advancements in its whole health approach and corporate governance.

Summary

• Elevance Health's 2025 operating revenue was $197.6 billion, a 13% increase over 2024, with an operating gain of $7.2 billion.
• The company returned $4.1 billion to shareholders in 2025 through share repurchases and dividends.
• Elevance Health ended 2025 with approximately 45.2 million medical members.
• Carelon, the company's health services platform, achieved approximately 33% operating revenue growth and 17% operating gain growth year-over-year.
• Payment Year 2027 Medicare Stars results improved, with 59% of Medicare Advantage members in 4+ Star plans as of January 1, 2026, up from 40% in the prior year.
• The Board recommends voting FOR the election of three directors (Gail K. Boudreaux, Robert L. Dixon, Jr., Deanna D. Strable), FOR the advisory vote on executive compensation, FOR the ratification of Ernst & Young LLP as auditors for 2026, and AGAINST a shareholder proposal requesting an independent study on political contributions.
• Over 85% of associates utilized the new Enterprise Skills Academy development platform, focusing on future-ready and core skills, including AI adoption.
• The company received the Great Place to Work certification for the sixth consecutive year and was recognized on Fortune's 2025 100 Best Companies to Work For list.
• The Elevance Health Foundation announced a $150 million, five-year commitment in 2025 to strengthen efforts in creating healthier communities.
• Approximately $121 million was committed to affordable housing projects in 2025, expected to lead to the construction of more than 560 affordable housing units.
• A pay equity analysis in 2025 found that among U.S. associates, pay for women and people of color is more than 99 cents for every dollar earned by men and white associates, respectively.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as generally positive due to strong revenue and operating gain growth, significant capital return, and robust performance in the Carelon segment, despite the miss on the Adjusted Shareholders' Net Income PSU target which was attributed to industry-wide headwinds.

Positives

• Strong financial performance in 2025 with $197.6 billion in operating revenue (13% increase over 2024) and a $7.2 billion operating gain.
• Significant capital returned to shareholders, totaling $4.1 billion through share repurchases and dividends.
• Robust growth in the Carelon health services platform, delivering 33% operating revenue growth and 17% operating gain growth year-over-year.
• Improved Medicare Stars results, with 59% of Medicare Advantage members in 4+ Star plans as of January 1, 2026, a substantial increase from 40% in the prior year.
• High associate engagement and development, with over 85% utilizing the new Enterprise Skills Academy development platform.
• Consistent recognition as a top employer, including Great Place to Work certification for the sixth consecutive year and inclusion on Fortune's 100 Best Companies to Work For list.
• Demonstrated commitment to community health through the Elevance Health Foundation's $150 million, five-year commitment and $121 million invested in affordable housing projects.
• Achieved pay equity, with women and people of color earning more than 99 cents for every dollar earned by men and white associates, respectively.
• Strong corporate governance practices, including an independent Board Chair, 11 of 12 independent directors, and fully independent key committees.

Negatives

• The 2023-2025 cumulative Adjusted Shareholders' Net Income of $22,366 million missed the threshold of $24,750 million for the Performance Stock Unit (PSU) awards.
• Medicaid cost trend increased more than 200% over the 2023-2025 performance period from the historical average, which was unprecedented and unanticipated, impacting Adjusted Shareholders' Net Income.
• The final 2023-2025 PSU payout was 62.5% of target, which was below the 100% target, even after an upward adjustment by the Compensation and Talent Committee due to industry headwinds.
• The Board recommended against a shareholder proposal requesting an independent study on the impact of prohibiting corporate contributions to partisan 527 tax-exempt political groups, indicating potential shareholder dissent on political spending transparency.

Risks

• The healthcare industry continues to face rising medical costs, greater administrative complexity, and growing demand for more personalized, accessible care.
• Risks associated with the development, governance, deployment, and use of AI solutions, as well as cybersecurity risks, are overseen by the Board and Audit Committee.
• Exposure to major risks related to financials, strategies, information technology, security, compliance, privacy, ethics, AI, reputation, and other operational risks.
• Risks associated with the company's capital structure, financial policies, financing strategies, and financial condition.
• Risks related to compensation policies, practices, and plans, although the Compensation and Talent Committee concluded they do not create material adverse effects.
• Potential for significant financial or reputational harm due to misconduct or violation of restrictive covenants by executive officers, leading to clawback provisions.
• Operating in a highly-regulated industry with federal, state, and international laws guiding the collection, use, and disclosure of confidential information.
• Impacts of environmental exposures on health and healthcare costs, such as extreme heat and wildfire smoke.
• Potential for political contributions to partisan 527 tax-exempt political groups to be redirected to support activities not intended by the company, raising reputational and other risks.
• Challenges and advisability of changing Independent Auditors, including the time and expense of transitioning to a new firm.

Future Outlook

Elevance Health aims to simplify the healthcare experience, make care more affordable, strengthen its healthcare services business, and expand innovative care models for sustainable long-term growth. The company is focused on improving health outcomes, containing costs, and reducing friction in the healthcare ecosystem, guided by its purpose to improve the health of humanity and deliver long-term shareholder value through strategic execution and prudent capital management.

Management Comments

• "We look forward to welcoming you to Elevance Healths 2026 Annual Meeting of Shareholders on May 13, 2026, at 8:00 a.m. Eastern Time. Your perspective matters to us, and we encourage you to review the proxy materials and vote at your earliest convenience."
• "Healthcare is at a pivotal moment. The industry continues to face rising medical costs, greater administrative complexity, and growing demand for more personalized, accessible care."
• "We remain firmly focused on making healthcare simpler and more affordable."
• "We believe we are well positioned to deliver shareholder value as the healthcare environment continues to evolve."
• "Our Board and management team recognize that culture is foundational to long-term success."
• "We remain disciplined and resolute in our goal to simplify the healthcare experience and make care more affordable."
• "Our purpose, passion, and commitment to being a lifetime, trusted health partner for those we are privileged to serve will guide our work today and continue to produce shareholder value over the long term through execution of our strategy and prudent capital management."

Industry Context

StockSavvy.ai notes that Elevance Health's focus on value-based care, streamlining prior authorizations, and leveraging digital tools like Sydney Health aligns with broader industry trends towards cost containment, improved patient experience, and digital transformation. The significant growth in its Carelon health services platform indicates a strategic shift towards integrated care solutions, a common theme among large healthcare providers seeking to diversify revenue streams and control the entire healthcare journey. The challenges faced with rising Medicaid costs and regulatory uncertainty are sector-wide issues, impacting many managed care organizations.

Comparison to Industry Standards

• Elevance Health's 2025 operating revenue growth of 13% and operating gain of $7.2 billion demonstrate strong performance in a dynamic operating environment, positioning it favorably against competitors navigating similar cost pressures.
• The 33% operating revenue growth and 17% operating gain growth in Carelon, the health services platform, significantly outpace typical growth rates for established healthcare segments, indicating successful scaling of innovative care models.
• Improving Payment Year 2027 Medicare Stars results to 59% of Medicare Advantage members in 4+ Star plans, up from 40% in the prior year, shows a strong competitive improvement in quality ratings, which are crucial for attracting and retaining Medicare members compared to peers like UnitedHealth Group or Humana.
• The company's ranking of #2 of 6 in Adjusted Shareholders' Earnings Per Diluted Share Growth and #1 of 6 in GAAP Shareholders' Net Income Growth (2023-2025 relative peer performance) within its Direct Industry Group (including Centene, CVS Health, Humana, The Cigna Group, UnitedHealth Group) indicates superior profitability growth compared to most direct competitors, despite missing the internal PSU target for Adjusted Shareholders' Net Income.
• The Total Shareholder Return ranking of #3 of 6 within its Direct Industry Group suggests a middle-of-the-pack performance in shareholder value creation over the 2023-2025 period, indicating room for improvement relative to top-tier peers.
• The commitment of $150 million over five years to the Elevance Health Foundation and $121 million to affordable housing projects in 2025 demonstrates a strong ESG commitment, potentially exceeding the social impact investments of some industry peers.

Management Changes

Corporate Governance

Related Party Transactions

• In the ordinary course of business, the company may engage in transactions with other companies whose officers or directors are also company directors or immediate family members of directors.
• In 2025, all such transactions came within the pre-approval procedures of the Governance Committee or the director did not have a material direct or indirect interest in the transaction.

Stakeholder Impact

• Shareholders: Directly impacted by $4.1 billion returned through share repurchases and dividends, and the company's stated focus on long-term shareholder value creation. The advisory vote on executive compensation provides a direct channel for shareholder input.
• Consumers/Members: Positively impacted by the company's whole health strategy, value-based care arrangements, digital engagement platform (Sydney Health), and social impact programs aimed at improving health outcomes, affordability, accessibility, and overall experience.
• Associates: Benefit from significant investment in human capital development, including the Enterprise Skills Academy and AI fluency certifications, a fair pay workplace, and a focus on fostering an inclusive and trusting environment, as evidenced by Great Place to Work recognition.
• Care Providers: Collaboration efforts to streamline prior authorization requirements, reduce administrative burden, and improve digital tools like HealthOS aim to enhance their experience and allow greater focus on patient care.
• Communities: Positively impacted by the Elevance Health Foundation's $150 million commitment, affordable housing investments, and Community Connected Care program, which address social needs and improve population health.
• Environment: The company's commitment to healthcare decarbonization, sourcing 100% renewable electricity, engaging suppliers on GHG reduction goals, and studying environmental exposure impacts on health demonstrates a positive environmental impact.

Next Steps

• The 2026 Annual Meeting of Shareholders will be held on May 13, 2026, at 8:00 a.m. Eastern Time.
• Shareholders will vote on the election of three directors, an advisory vote to approve executive compensation, the ratification of Ernst & Young LLP as auditors for 2026, and a shareholder proposal on political contributions.
• The Board will continue to assess Board composition against the company's evolving strategy and shareholder priorities.
• The company plans to continue strengthening its healthcare services business and expanding innovative care models for sustainable long-term growth.
• The company will continue to promote solutions that improve health outcomes, contain costs, and reduce friction across the healthcare ecosystem.
• The next Say-on-Pay frequency vote will be held at the 2029 Annual Meeting of Shareholders.
• Shareholder proposals for inclusion in the 2027 proxy materials must be received by November 27, 2026.
• Notice of proxy access director nominees for the 2027 Annual Meeting must be received between October 28, 2026, and December 27, 2026.
• Other shareholder proposals and nominations for the 2027 Annual Meeting must be delivered between January 13, 2027, and February 12, 2027.
• Shareholders intending to solicit proxies in support of director nominees must provide notice by March 15, 2027.

Key Dates

Recommendation

Elevance Health demonstrates solid financial performance with strong revenue growth and significant capital returns, alongside strategic advancements in its Carelon platform and Medicare Stars ratings. However, the miss on the Adjusted Shareholders' Net Income PSU target, even with committee adjustments for industry headwinds, indicates underlying challenges in profitability management amidst a dynamic healthcare environment. The stock appears to be well-managed with good governance, but the mixed performance signals suggest a 'hold' position until there is clearer evidence of sustained profitability improvement despite industry pressures.

Keywords

Healthcare, Health Insurance, Elevance Health, Proxy Statement, Financial Performance, Corporate Governance, Executive Compensation, Risk Management, Sustainability, Medicare Advantage, Medicaid, Carelon, AI Governance, Shareholder Meeting, ESG, Blue Cross Blue Shield